| CASPER PHARMA, LLC |
70199002114 |
HELIDAC THERAPY CHEW/TAB/CAP 224 |
2020-06-24 |
966.0000 |
Casper Pharma engages in strategic marketing to create awareness and understanding with healthcare providers and pharmacies about the approved indication, efficacy and safety data contained within the drug's FDA approved label.
We employ a comparative pricing model as compared to other H-Pylori therapies in the market. Our mission is to ensure a favorable patient cost benefit while also providing broad patient and market access. |
None |
59000 |
None |
None |
2017-07-18 |
0.0000 |
1 |
Trade Secret |
Additional Comments Relative to Estimated Number of Patients:
1. Per the attached Product Insert for HELIDAC, this therapy is indicated for treatment of H-Pylori & Duodenal Ulcers.
2. Out of total US population of ~340 Million, H-Pylori prevalence pool is ~35% which is about ~119 Million people.
Source for estimates https://publichealth.arizona.edu/outreach/health-literacy-awareness/hpylori/prevalence#:~:text=pylori%20prevalence%20is%2060%20percent,those%20older%20than%2060%20years.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3107911/
3. Although there is wide prevalence of H-Pylori, only ~10% of the prevalent pool are symptomatic. There are high chances of misdiagnosis based on symptoms alone and often acid suppressants or OTCs are prescribed for prevention of ulcers.
4. Our source of the market data is the industry standard, IQVIA data. During the time period Dec 2018 to Nov 2019, there have been a total of 59,534 patients diagnosed and undergoing treatment for H Pylori, with a total of 61,748 prescriptions filled with a drug from the same therapeutic class.
5. Despite high incidence and wide prevalence, the treatment choice is limited by wide spread resistance to some of the drugs and also the availability of other multi drug regimens and OTCs. |
None |
| Celltrion USA, Inc. |
72606055902 |
Busulfan Injection 60 mg/10 mL |
2020-02-04 |
1496.0100 |
N/A - generic product |
None |
33000 |
1 |
None |
None |
None |
None |
None |
Celltrion USA has confirmed that they are responsible for setting the WAC. Also, there are or may be other manufacturers selling these products under a different labeler code. |
None |
| Chiesi USA |
10122010401 |
FERRIPROX tablets twice-a-day 1000mg |
2020-07-02 |
8590.1500 |
None |
1 |
650 |
None |
None |
None |
None |
None |
None |
Acquired while in development; Approved while owned by Chiesi USA. |
None |
| Cipla USA, Inc. |
69097096453 |
Vigabatrin Powd Pack 500 MG, 50 Each, Unit-Dose, Box |
2020-04-30 |
1337.0600 |
None |
1 |
7500000 |
None |
1 |
None |
None |
None |
None |
Product was not acquired |
None |
| Cipla USA, Inc. |
69097082037 |
Plazomicin Sulfate IV Soln 500 MG/10ML (50 MG/ML) (Base Eq), 10 ML, Unit-Dose, Vial |
2020-05-01 |
315.0000 |
None |
1 |
20 |
None |
None |
None |
None |
None |
None |
Estimated number of patients is considered a trade secret and non-public information. This information is not generally known or disclosed publicly and is of a highly sensitive and competitive nature that are confidential and proprietary trade secrets. Cipla provides this information solely for purposes of compliance with applicable reporting requirements mandated by state law. Any authorized disclosure of this sensitive information would be against Cipla’s express objection and a misappropriation of Cipla’s trade secrets. |
None |
| Cipla USA, Inc. |
69097082096 |
Plazomicin Sulfate IV Soln 500 MG/10ML (50 MG/ML) (Base Eq), 10 ML, Unit-Dose, Vial Qty 10 |
2020-05-01 |
3150.0000 |
None |
1 |
20 |
None |
None |
None |
None |
None |
None |
Estimated number of patients is considered a trade secret and non-public information. This information is not generally known or disclosed publicly and is of a highly sensitive and competitive nature that are confidential and proprietary trade secrets. Cipla provides this information solely for purposes of compliance with applicable reporting requirements mandated by state law. Any authorized disclosure of this sensitive information would be against Cipla’s express objection and a misappropriation of Cipla’s trade secrets. |
None |
| Cipla USA, Inc. |
69097050327 |
Dihydroergotamine Mesylate Nasal Spray, 4 mg/mL |
2020-05-23 |
3426.8400 |
None |
1 |
1700 |
None |
None |
None |
None |
None |
None |
Drug was not acquired. Estimated number of patients is 1,700 per month |
None |
| Cipla USA, Inc. |
69097066434 |
Icatibant Acetate Subcutaneous Solution 30 MG/3ML |
2020-07-20 |
5083.2600 |
None |
1 |
10000 |
None |
None |
None |
None |
None |
None |
Product not acquired |
None |
| Cipla USA, Inc. |
69097032303 |
Dimethyl Fumarate Oral Capsule Delayed Release 240 MG |
2020-09-25 |
2607.1600 |
None |
1 |
1000000 |
None |
None |
None |
None |
None |
None |
Drug not acquired |
None |
| Cipla USA, Inc. |
69097055203 |
Dimethyl Fumarate Starter Pack Oral Miscellaneous 120 & 240 MG |
2020-09-25 |
2607.1600 |
None |
1 |
1000000 |
None |
None |
None |
None |
None |
None |
Drug not acquired |
None |
| Cipla USA, Inc. |
69097066468 |
Icatibant Acetate Subcutaneous Solution 30 MG/3ML 3x3ml |
2020-11-03 |
15249.7800 |
None |
1 |
10000 |
None |
None |
None |
None |
None |
None |
Product was not acquired |
None |